Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
Treating hormone receptor-positive breast cancer with an aromatase inhibitor, or AI, usually used only in postmenopausal women, significantly reduced breast cancer return in premenopausal women when used with ovarian suppression , according to the preliminary reports of two combined studies.
According to new research, a large percentage of women with breast cancer say the disease and its treatment costs have caused their financial situation to get worse, often leading to serious hardships. This is especially true for black and Latina women.
Most young women diagnosed with early-stage breast cancer are at risk of becoming infertile from treatment, according to a study from the Centers for Disease Control and Prevention (CDC) and other researchers.
New findings may pave the way for people with stage IV breast cancer in the bones to receive bone-strengthening treatment less often. These results could mean decreased risk of side effects.
The American Society of Clinical Oncology published 3 new guidelines for physicians so they may better help people prevent or manage neuropathy, fatigue, depression and anxiety. These common cancer side effects may linger long after treatment.
The guidelines are based on ASCO’s review of published research and its assessment of risks and benefits for treatments. They are the first in a planned series of guidelines for caring for people who have any type of cancer. Here’s a look at each side effect and the new guideline for each:
Before and during chemotherapy, giving premenopausal women with estrogen receptor-negative (ER-) breast cancer the medicine goserelin (Zoladex) improved their ability to become pregnant several years after treatment and to deliver healthy babies.
Showing no sign of invasive cancer in the breast or nearby lymph nodes after treatment with pre-surgery chemotherapy may lead to longer survival, an analysis of 12 international studies suggests. This was most true for those with hormone receptor-negative, HR-negative, breast cancers.
To help doctors recommend treatment options based on research evidence and expert consensus, the American Society of Clinical Oncology released its first guidelines on treating metastatic HER2-positive breast cancer.
ASCO issued two clinical practice guidelines for this breast cancer type. One advises on systemic (whole body) therapies for HER2-positive breast cancer that has advanced outside of the breast, other than to the brain. The other recommends specifics on treating brain metastases.
LBBC highlights two studies reported on the last day of the annual meeting of the American Society of Clinical Oncology: GeparSixto, which looked at the impact of adding a platinum chemotherapy to standard medicines given before surgery to people with triple-negative breast cancer and a family history of breast or ovarian cancer; and an analysis of the PAM50 genomic assay as a tool to help people with early-stage breast cancer make decisions about mastectomy versus lumpectomy and radiation.
Sunday reports from the 50th annual meeting of the American Society of Clinical Oncology focused on using aromatase inhibitors in premenopausal women with early-stage, estrogen-positive breast cancer and on a negative study of lapatinib for HER2-positive early-stage disease.